Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and ABI-009 in Advanced Cancers
NCT03190174Phase 2Completed
- Sponsor
- Cancer Institute Medical Group
- Start
- Aug 2017
- Primary completion
- Dec 2021
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-sirolimus in Ewing sarcoma, perivascular epithelioid cell tumor (PEComa), epithelioid sarcoma (ES) and 12 more, sponsored by Cancer Institute Medical Group. Primary endpoint: Maximum Tolerated Dose of ABI-009 at Week 6. Started Aug 2017; status: completed.
02
Drugs
nab-sirolimus
03
Conditions
Ewing sarcomaperivascular epithelioid cell tumor (PEComa)epithelioid sarcoma (ES)desmoid tumorchordoma
Beyond the preview
Go deeper on NCT03190174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03190174.